Skip to main content
On February 12, 2019, Janssen announced that the Psychopharmacologic Drug Advisory Committee and Drug Safety and Risk Management Advisory Committee of the U.S. Food and Drug Administration (FDA) recommended approval of Janssen's SPRAVATO™ (esketamine) self-administered nasal spray for treatment-resistant depression (TRD) in adults. The FDA will consider the committee recommendation in making its final decision on Janssen's New Drug Application (NDA) that was submitted on September 4, 2018.  While the FDA is not bound by the committee's recommendation, it does take its advice into consideration. The FDA's decision is expected by March 4 . . .
Content Restricted

This article is reserved for members with an active Standard Membership. Please purchase a Standard Membership to view this resource.

Purchase A Standard Account

Tagged As:

Login to access The OPEN MINDS Circle Library. Not a member? Create your free account now!

Close

Support Request

Need help now?

Call our toll-free phone number 877-350-6463